ArticleAmerican journal of ophthalmology2019
Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.
Article in American journal of ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Formulation of treatment protocol for ocular surface squamous neoplasia.International ophthalmology · 2026Pooled it
- Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Protamine nanocapsules as gene delivery carriers for the treatment of intraocular tumors.Drug delivery and translational research · 2026Article
- Prolonged stability of 1% 5-FU eye drops as topical chemotherapy for ocular surface squamous neoplasia.The ocular surface · 2026Article
- Optical coherence tomography angiography in evaluating the response of ocular surface squamous neoplasia to topical immunotherapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Identification of dysregulated gene clusters and pathways driving ocular surface squamous neoplasia progression.Scientific reports · 2025Article
- Topical 5-fluorouracil 1% versus surgical removal as a primary treatment modality for ocular surface squamous neoplasia: a comparison of recurrences and side effects.BMC ophthalmology · 2025Article
- Management and outcomes of ocular surface squamous neoplasia at a tertiary hospital, South Africa.Eye (London, England) · 2025Article
- A pH-Responsive Poly Beta-Amino Ester Nanoparticulate Thermo-Responsive PEG-PCL-PEG Hydrogel Dispersed System for the Delivery of Interferon Alpha to the Ocular Surface.Pharmaceutics · 2025Article
- Interferon alpha-2b versus 5-fluorouracil as primary treatment modalities for ocular surface squamous neoplasia: a study of 116 eyes.International ophthalmology · 2025Article
- Update in the Diagnosis and Management of Ocular Surface Squamous Neoplasia (OSSN).Journal of clinical medicine · 2025Review
- Oncological principles in the management of ocular surface squamous neoplasia - A Review.Indian journal of ophthalmology · 2025Review
- Infectious etiologies of conjunctival tumors.Expert review of ophthalmology · 2025Article
- Clinical profile and outcomes of ocular surface squamous neoplasia at the Philippine General Hospital: a retrospective study.International journal of ophthalmology · 2025Article
- Article
- Article
- Treatment of ocular surface squamous neoplasia in an Indian rural facility: a study of 38 eyes.BMC ophthalmology · 2024Article
- Clinicopathological Correlates of Ocular Surface Squamous Neoplasia.Ocular oncology and pathology · 2024Article
- Corneal squamous neoplasia: masquerades and management outcomes at a rural eyecare centre.BMJ case reports · 2023Article
- Medical treatment for ocular surface squamous neoplasia.Eye (London, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo compare the efficacy of topical 5-fluorouracil 1% (5FU) and interferon alfa-2b 1 MIU/mL (IFN) eye drops as primary treatment modalities for ocular surface squamous neoplasia (OSSN).
designRetrospective, comparative, interventional case series.
methodsFifty-four patients who received 5FU and 48 patients who received IFN as primary therapy for OSSN were included. Primary outcome measures were the frequency of clinical resolution and time to OSSN recurrence by treatment modality. Secondary outcome was the frequency of side effects with each therapy.
resultsThe mean age of patients was 68 years. More Hispanics were treated with 5FU. In a univariable analysis, frequency of OSSN resolution was higher with 5FU (96.3%, n = 52) than with IFN (81.3%, n = 39), P = .01. In a multivariable analysis, treatment modality did not remain a significant predictor of resolution. In patients whose OSSN resolved, time to resolution was similar with both agents, (5FU mean 6.6 months, standard deviation (SD) 4.5 vs IFN mean 5.5 months, SD 2.9, P = .17). Of the 52 eyes whose OSSN resolved with 5FU, 11.5% of lesions (n = 6) recurred, whereas of the 39 eyes whose OSSN resolved with IFN, 5.1% of lesions (n = 2) recurred, P = .46. Kaplan-Meier survival curves of OSSN recurrence were similar between groups (log-rank = 0.16). One-year recurrence rates were 11.4% with 5FU and 4.5% with IFN. Eyelid edema (P = .04) and tearing (P = .02) were more significant with 5FU.
conclusionsThis is the first direct comparison study between 5FU and IFN eye drops as primary treatment modalities for OSSN. Both modalities resulted in a high frequency of tumor resolution and low recurrence rates and are effective treatment options for OSSN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.